Protecting APOBEC3G: A potential new target for HIV drug discovery

Current Opinion in Investigational Drugs

Volumn 6, Issue 2, 2005, Pages 141-147

  Stopak, Kimberly ^a   Greene, Warner C ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Aids; Antiviral; APOBEC3G; DNA editing; HIV 1; Vif

Indexed keywords

APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 1; CULLIN; CYTIDINE DEAMINASE; ELONGIN B; ELONGIN C; PROTEASOME; PROTEIN APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3G; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG; VIF PROTEIN; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CEM15 PROTEIN, HUMAN; DEAMINASE; PROTEIN; REPRESSOR PROTEIN;

DRUG TARGETING; ENZYME REPRESSION; GENE MUTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOCOMPETENT CELL; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; REVERSE TRANSCRIPTION; REVIEW; UBIQUITINATION; VIRUS INFECTIVITY; VIRUS REPLICATION; ANIMAL; DRUG EFFECT; PATHOGENICITY; PHYSIOLOGY; VIROLOGY;

ANIMALS; ANTI-HIV AGENTS; HIV INFECTIONS; HIV-1; HUMANS; NUCLEOSIDE DEAMINASES; PROTEINS; REPRESSOR PROTEINS;

EID: 15744395886     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (39)

1. Harris RS, Bishop KN, Sheehy AM, Craig HM, Petersen-Mahrt SK, Watt IN, Neuberger MS, Malim MH: DNA deamination mediates innate immunity to retroviral infection. Cell (2003) 113(6):803-809. This paper, along with references [2••,4••,5••], was the first to report that APOBEC3G targets viral single-stranded DNA formed during reverse transcription.
2. Zhang H, Yang B, Pomerantz RJ, Zhang C, Arunachalam SC, Gao L: The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. Nature (2003) 424(6944):94-98. This paper, along with references [1••,4••,5••], was the first to report that APOBEC3G targets viral single-stranded DNA formed during reverse transcription.
3. Sheehy AM, Gaddis NC, Choi JD, Malim MH: Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature (2002) 418(6898):646-650. The identification of APOBEC3G (originally known as CEM15) and its anti-HIV-1 activity was pioneering research that generated a series of subsequent advances in the field.
4. Mangeat B, Turelli P, Caron G, Friedli M, Perrin L, Trono D: Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature (2003) 424(6944):99-103. This paper, along with references [1••,2••,5••], was the first to report that APOBEC3G targets viral single-stranded DNA formed during reverse transcription.
5. Lecossier D, Bouchonnet F, Clavel F, Hance AJ: Hypermutation of HIV-1 DNA in the absence of the Vif protein. Science (2003) 300(5622):1112. This paper, along with references [1••,2••,4••], was the first to report that APOBEC3G targets viral single-stranded DNA formed during reverse transcription.
6. Stopak K, de Noronha C, Yonemoto W, Greene WC: HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability. Mol Cell (2003) 12(3):591-601. This study demonstrated that HIV-1 Vif causes the depletion of endogenous APOBEC3G from infected cells by both accelerating its degradation by the 26S proteasome and by partially inhibiting its synthesis.
7. Sheehy AM, Gaddis NC, Malim MH: The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nat Med (2003) 9(11):1404-1407. This paper, along with reference [8••], reports that Vif depletes APOBEC3G from cells by promoting its polyubiquitylation.
8. Marin M, Rose KM, Kozak SL, Kabat D: HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation. Nat Med (2003) 9(11):1398-1403. This paper, along with reference [7••], reports that Vif depletes APOBEC3G from cells by promoting its polyubiquitylation.
9. Yu X, Yu Y, Liu B, Luo K, Kong W, Mao P, Yu XF: Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex. Science (2003) 302(5647):1056-1060. This paper describes in detail the E3 ligase complex that Vif recruits to APOBEC3G.
10. Mehle A, Strack B, Ancuta P, Zhang C, McPike M, Gabuzda D: Vif overcomes the innate antiviral activity of APOBEC3G by promoting its degradation in the ubiquitin-proteasome pathway. J Biol Chem (2004) 279(9):7792-7798.
11. Conticello SG, Harris RS, Neuberger MS: The Vif protein of HIV triggers degradation of the human antiretroviral DNA deaminase APOBEC3G. Curr Biol (2003) 13(22):2009-2013.
12. Gabuzda DH, Lawrence K, Langhoff E, Terwilliger E, Dorfman T, Haseltine WA, Sodroski J: Role of VIf in replication of human immunodeficiency virus type 1 in CD4+ T lymphocytes. J Virol (1992) 66(11):6489-6495.
13. Fisher AG, Ensoli B, Ivanoff L, Chamberlain M, Petteway S, Ratner L, Gallo RC, Wong-Staal F: The sor gene of HIV-1 is required for efficient virus transmission in vitro. Science (1987) 237(4817):888-893.
14. Strebel K, Daugherty D, Clouse K, Cohen D, Folks T, Martin MA: The HIV 'A' (sor) gene product is essential for virus infectivity. Nature (1987) 328(6132):728-730.
15. Aldrovandi GM, Zack JA: Replication and pathogenicity of human immunodeficiency virus type 1 accessory gene mutants in SCID-hu mice. J Virol (1996) 70(3):1505-1511.
16. Desrosiers RC, Lifson JD, Gibbs JS, Czajak SC, Howe AY, Arthur LO, Johnson RP: Identification of highly attenuated mutants of simian immunodeficiency virus. J Virol (1998) 72(2):1431-1437.
17. Simon F, Mauclere P, Roques P, Loussert-Ajaka I, Muller-Trutwin MC, Saragosti S, Georges-Courbot MC, Barre-Sinoussi F, Brun-Vezinet F: Identification of a new human immunodeficiency virus type 1 distinct from group M and group O. Nat Med (1998) 4(9):1032-1037.
18. Madani N, Kabat D: An endogenous inhibitor of human immunodeficiency virus in human lymphocytes is overcome by the viral Vif protein. J Virol (1998) 72(12):10251-10255.
19. Mariani R, Chen D, Schrofelbauer B, Navarro F, Konig R, Bollman B, Munk C, Nymark-McMahon H, Landau NR: Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif. Cell (2003) 114(1):21-31. This was the first paper to describe diminished encapsidatlon of APOBEC3G in virions produced by cells expressing Vif.
20. Dussart S, Courcoul M, Bessou G, Douaisi M, Duverger Y, Vigne R, Oecroly E: The Vif protein of human immunodeficiency virus type 1 is posttranslationally modified by ubiquitin. Biochem Biophys Res Commun (2004) 315(1):66-72.
21. Jarmuz A, Chester A, Bayliss J, Gisboume J, Dunham I, Scott J, Navaratnam N: An anthropoid-specific locus of orphan C to U RNA-editing enzymes on chromosome 22. Genomics (2002) 79(3):285-296. This paper compares the properties of various APOBEC3 proteins and provides some biochemical studies of APOBEC3G.
22. Harris RS, Petersen-Mahrt SK, Neuberger MS: RNA editing enzyme APOBEC1 and some of its homologs can act as DNA mutators. Mol Cell (2002) 10(5):1247-1253.
23. Krokan HE, Drablos F, Slupphaug G: Uracil in DNA - occurrence, consequences and repair. Oncogene (2002) 21(58):8935-8948.
24. Petersen-Mahrt SK, Harris RS, Neuberger MS: AID mutates E coli suggesting a DNA deamination mechanism for antibody diversification. Nature (2002) 418(6893):99-103.
25. Klarmann GJ, Chen X, North TW, Preston BD: Incorporation of uracil into minus strand DNA affects the specificity of plus strand synthesis initiation during lentiviral reverse transcription. J Biol Chem (2003) 278(10):7902-7909.
26. Bouhamdan M, Benichou S, Rey F, Navarro JM, Agostini I, Spire B, Camonis J, Slupphaug G, Vigne R, Benarous R, Sire J: Human immunodeficiency virus type 1 Vpr protein binds to the uracil DNA glycosylase DNA repair enzyme. J Virol (1996) 70(2):697-704.
27. Turelli P, Mangeat B, Jost S, Vianin S, Trono D: Inhibition of hepatitis B virus replication by APOBEC3G. Science (2004) 303(5665):1829.
28. Bishop KN, Holmes RK, Sheehy AM, Davidson NO, Cho SJ, Malim MH: Cytidine deamination of retroviral DNA by diverse APOBEC proteins. Curr Biol (2004) 14(15):1392-1396.
29. Zheng YH, Irwin D, Kurosu T, Tokunaga K, Sata T, Peterlin BM: Human APOBEC3F is another host factor that blocks human immunodeficiency virus type 1 replication. J Virol (2004) 78(11):6073-6076.
30. Wiegand HL, Doehle BP, Bogerd HP, Cullen BR: A second human antiretroviral factor, APOBEC3F, is suppressed by the HIV-1 and HIV-2 Vif proteins. EMBO J (2004) 23(12):2451-2458.
31. Liddament MT, Brown WL, Schumacher AJ, Harris RS: APOBEC3F properties and hypermutation preferences indicate activity against HIV-1 in vivo. Curr Biol (2004) 14(15):1385-1391.
32. Yu Q, Chen D, Konig R, Mariani R, Unutmaz D, Landau NR: APOBEC3B and APOBEC3C are potent inhibitors of simian immunodeficiency virus replication. J Biol Chem (2004) 279(51):53379-53386.
33. Janini M, Rogers M, Birx DR, McCutchan FE: Human immunodeficiency virus type 1 DNA sequences genetically damaged by hypermutation are often abundant in patient peripheral blood mononuclear cells and may be generated during near-simultaneous infection and activation of CD4+ T cells. J Virol (2001) 75(17):7973-7986.
34. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, Kong N, Kammlott U, Lukacs C, Klein C, Fotouhi N, Liu EA: In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science (2004) 303(5659):844-848.
35. Schrofelbauer B, Chen D, Landau NR: A single amino acid of APOBEC3G controls its species-specific interaction with virion infectivity factor (Vif). Proc Natl Acad Sci USA (2004) 101(6):3927-3932.
36. Mangeat B, Turelli P, Liao S, Trono D: A single amino acid determinant governs the species-specific sensitivity of APOBEC3G to Vif action. J Biol Chem (2004) 279(15):14481-14483.
37. Bogerd HP, Doehle BP, Wiegand HL, Cullen BR: A single amino acid difference in the host APOBEC3G protein controls the primate species specificity of HIV type 1 virion infectivity factor. Proc Natl Acad Sci USA (2004) 101(11):3770-3774.
38. Xu H, Svarovskaia ES, Barr R, Zhang Y, Khan MA, Strebel K, Pathak VK: A single amino acid substitution in human APOBEC3G antiretroviral enzyme confers resistance to HIV-1 virion infectivity factor-induced depletion. Proc Natl Acad Sci USA (2004) 101(15):5652-5657.
39. Yamanaka S, Balestra ME, Ferrell LD, Fan J, Arnold KS, Taylor S, Taylor JM, Innerarity TL: Apolipoprotein B mRNA-editing protein induces hepatocellular carcinoma and dysplasia in transgenic animals. Proc Natl Acad Sci USA (1995) 92(18):8483-8487.